Zynerba Pharmaceuticals, Inc. ZYNE
Set alert
1.30 +1.30 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 70.12M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -2.28
- Beta
- 1.19
- Short ratio
- 0.45
- Inst. own
- 12.13%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 13, 2023
- 50-d avg
- 1.21
- 200-d avg
- 0.62141
- 1y target
- 1.25
2Y chart
Events in this range
- Jun 22, 2022Rating: Canaccord Genuity · — → Buy
- Aug 10, 2022Earnings: —; estimate -0.21; surprise —%
- Nov 14, 2022Earnings: —; estimate -0.21; surprise —%
- Mar 28, 2023Earnings: —; estimate -0.24; surprise —%
- May 15, 2023Earnings: —; estimate -0.2; surprise —%
- Aug 14, 2023Earnings: —; estimate -0.2; surprise —%
- Aug 14, 2023Downgrade: HC Wainwright & Co. · Buy → Neutral
- Aug 15, 2023Downgrade: Canaccord Genuity · Buy → Hold
Signals (67)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Sep 1, 2023 | 3 years ago |
| SMA: Bullish | Aug 14, 2023 | 3 years ago |
| SMA: Bullish | Aug 14, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 14, 2023 | 3 years ago |
| RSI: Overbought | Aug 14, 2023 | 3 years ago |
| SMA: Bearish | Aug 9, 2023 | 3 years ago |
| SMA: Bullish | Aug 8, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 3, 2023 | 3 years ago |
| SMA: Bullish | Jul 14, 2023 | 3 years ago |
| SMA: Bearish | Jul 12, 2023 | 3 years ago |
| SMA: Bullish | Jul 11, 2023 | 3 years ago |
| SMA: Bearish | Jul 10, 2023 | 3 years ago |
| SMA: Bullish | Jul 5, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 3, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 27, 2023 | 3 years ago |
| MACD: Buy Signal | May 26, 2023 | 3 years ago |
| RSI: Oversold | May 19, 2023 | 3 years ago |
| MACD: Sell Signal | May 16, 2023 | 3 years ago |
| MACD: Buy Signal | May 10, 2023 | 3 years ago |
| MACD: Sell Signal | May 3, 2023 | 3 years ago |
| MACD: Buy Signal | May 2, 2023 | 3 years ago |
| MACD: Sell Signal | May 1, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 28, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 26, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 17, 2023 | 3 years ago |
| SMA: Bearish | Feb 9, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 7, 2023 | 3 years ago |
| SMA: Bullish | Jan 13, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 4, 2023 | 3 years ago |
| MACD: Sell Signal | Dec 23, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 28, 2022 | 3 years ago |
| RSI: Oversold | Nov 18, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 16, 2022 | 3 years ago |
| MACD: Buy Signal | Oct 17, 2022 | 4 years ago |
| RSI: Oversold | Oct 13, 2022 | 4 years ago |
| RSI: Oversold | Oct 11, 2022 | 4 years ago |
| RSI: Oversold | Sep 21, 2022 | 4 years ago |
| SMA: Bearish | Aug 29, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 22, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 5, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 29, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 21, 2022 | 4 years ago |
| SMA: Bullish | Jul 14, 2022 | 4 years ago |
| SMA: Bearish | Jul 13, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 12, 2022 | 4 years ago |
| SMA: Bullish | Jun 23, 2022 | 4 years ago |
| MACD: Buy Signal | May 20, 2022 | 4 years ago |
| MACD: Sell Signal | May 6, 2022 | 4 years ago |
| RSI: Oversold | May 5, 2022 | 4 years ago |
| MACD: Buy Signal | May 4, 2022 | 4 years ago |
| RSI: Oversold | May 3, 2022 | 4 years ago |
| RSI: Oversold | Apr 20, 2022 | 4 years ago |
| RSI: Oversold | Apr 18, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 8, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 17, 2022 | 4 years ago |
| RSI: Oversold | Mar 15, 2022 | 4 years ago |
| RSI: Oversold | Mar 2, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 22, 2022 | 4 years ago |
| MACD: Buy Signal | Jan 25, 2022 | 4 years ago |
| RSI: Oversold | Jan 18, 2022 | 4 years ago |
| RSI: Oversold | Jan 12, 2022 | 4 years ago |
| RSI: Oversold | Jan 7, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 5, 2022 | 4 years ago |
| RSI: Oversold | Jan 5, 2022 | 4 years ago |
| MACD: Buy Signal | Jan 3, 2022 | 4 years ago |
| MACD: Sell Signal | Dec 30, 2021 | 4 years ago |
Key statistics
- Market cap
- 70.12M
- Enterprise value
- 29.85M
- Trailing P/E
- 0.00
- Forward P/E
- -2.28
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.26
- EPS (TTM)
- -0.79
- Beta
- 1.19
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -18.79M
- Total cash
- 35.97M
- Total debt
- 217.88K
- Return on equity
- -87.13%
- Shares outstanding
- 53.94M
- Short % of float
- 0.83%
- 50-day average
- 1.21
- 200-day average
- 0.62141
Analyst view
Consensus: hold
Hold
Price target (mean) 1.25 -3.8% downside
Now 1.30
- Target (low)
- 1.11
- Target (mean)
- 1.25
- Target (high)
- 1.40
Ratings (0m) 7 4 buy · 3 hold · 0 sell
- Strong buy1
- Buy3
- Hold3
- Sell0
- Strong sell0
Next earnings
Nov 13, 2023
Expected Nov 13, 2023. Consensus EPS estimate 0.19.
Financials — quick view
ZYNE Revenue — quarterly 0
ZYNE Net income — quarterly -10.78M
ZYNE EPS — quarterly -0.21
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2023 | Sep 1, 2023 | -0.20 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -0.20 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -0.20 | — | — | — |
| Mar 28, 2023 | Dec 1, 2022 | -0.24 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.21 | — | — | — |
| Aug 10, 2022 | Jun 1, 2022 | -0.21 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2023 | Canaccord Genuity | down | Buy | Hold |
| Aug 14, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 22, 2022 | Canaccord Genuity | main | — | Buy |
| Jun 30, 2020 | Needham | down | Buy | Hold |
| May 27, 2020 | Cantor Fitzgerald | main | — | Overweight |
| Oct 20, 2019 | Needham | init | — | Buy |
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. As of October 10, 2023, Zynerba Pharmaceuticals, Inc. operates as a subsidiary of Harmony Biosciences Holdings, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- zynerba.com
News
- 22q11.2 Deletion Syndrome Market Research Report 2025: Zynerba Pharmaceuticals is at the Forefront with Its Clinical-stage Therapy Zygel (ZYN002)
- Fragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery Partners
- Why Shares of Harmony Bioscience Are Falling on Friday
- HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
- Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
- Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
- HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
- Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
- ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
- ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
Your note
Sign in to keep a note on ZYNE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANIDO ARMANDO | Chief Executive Officer | Stock Award(Grant) | Oct 9, 2023 | 0 |
| COOPER WARREN D | Director | Sale | Jun 13, 2023 | 75,778 |
| FEDERICI WILLIAM J | Director | Sale | Jun 13, 2023 | 75,778 |
| FICKENSCHER JAMES E | Chief Financial Officer | Stock Award(Grant) | Oct 9, 2023 | 0 |
| JONES KENNETH T | Chief Financial Officer | Stock Award(Grant) | Oct 9, 2023 | 0 |
| KISNER DANIEL L | Director | Sale | Jun 13, 2023 | 75,778 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.04% | 2,179,600 | 710.55K | Jun 29, 2023 |
| Blackrock Inc. | 1.37% | 740,524 | 241.41K | Jun 29, 2023 |
| ETF Managers Group, LLC | 1.34% | 723,151 | 310.95K | Mar 30, 2023 |
| Renaissance Technologies, LLC | 1.28% | 689,713 | 224.85K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.72% | 387,346 | 126.27K | Jun 29, 2023 |
| Penserra Capital Management LLC | 0.41% | 220,858 | 72.00K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.82% | 1,521,801 | 496.11K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.12% | 604,155 | 196.95K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.44% | 238,972 | 79.82K | May 30, 2023 |
| Amplify Seymour Cannabis ETF | 0.41% | 220,858 | 80.61K | Jul 30, 2023 |
| Fidelity Total Market Index Fund | 0.10% | 56,274 | 18.80K | May 30, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.10% | 52,200 | 17.02K | Jun 29, 2023 |